#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	3256	16S	1529	1529	99.87	16S.l15.c17.ctg.1	1911	322.0	0	.	n	.	0	G1207A	SNP	1207	1207	G	1393	1393	A	411	A	265	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	3256	16S	1529	1529	99.87	16S.l15.c17.ctg.1	1911	322.0	0	.	n	.	0	C1450T	SNP	1450	1450	C	1636	1636	T	366	T	232	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	3256	16S	1529	1529	99.87	16S.l15.c17.ctg.1	1911	322.0	1	SNP	n	C1184T	0	.	.	1184	1184	C	1370	1370	C	376	C	243	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5920	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4034	279.6	0	.	n	.	0	G1337A	SNP	1337	1337	G	2061	2061	A	357	A	232	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5920	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4034	279.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2695	2695	C	342	C,T	219,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5920	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4034	279.6	1	SNP	n	A2045G	0	.	.	2045	2045	A	2769	2769	A	380	A	247	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5920	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4034	279.6	1	SNP	n	C2597T	0	.	.	2597	2597	C	3321	3321	C	345	C	234	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_F_01537c	folP.WHO_F_01537c	1	1	539	186	folP	852	852	99.77	folP.l15.c4.ctg.1	1453	24.6	0	.	p	.	0	D71H	NONSYN	211	213	GAT	554	556	CAT	20;20;20	C;A;T	14;12;14	.	.
folP.WHO_F_01537c	folP.WHO_F_01537c	1	1	539	186	folP	852	852	99.77	folP.l15.c4.ctg.1	1453	24.6	0	.	p	.	0	A204V	NONSYN	610	612	GCA	953	955	GTA	26;26;26	G;T;A	17;16;16	.	.
folP.WHO_F_01537c	folP.WHO_F_01537c	1	1	539	186	folP	852	852	99.77	folP.l15.c4.ctg.1	1453	24.6	1	SNP	p	R228S	0	.	.	682	684	CGC	1025	1027	CGC	22;22;23	C;G;C	14;14;15	folP.WHO_F_01537c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	470	gyrA	2751	2751	99.82	gyrA.l6.c4.ctg.1	3165	29.3	0	.	p	.	0	M250I	NONSYN	748	750	ATG	952	954	ATA	25;25;25	A;T;A	19;18;18	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	470	gyrA	2751	2751	99.82	gyrA.l6.c4.ctg.1	3165	29.3	1	SNP	p	S91F	0	.	.	271	273	TCC	475	477	TCC	61;61;61	T;C;C	34;35;35	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	470	gyrA	2751	2751	99.82	gyrA.l6.c4.ctg.1	3165	29.3	1	SNP	p	D95G	0	.	.	283	285	GAC	487	489	GAC	64;64;64	G;A;C	37;36;36	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	470	gyrA	2751	2751	99.82	gyrA.l6.c4.ctg.1	3165	29.3	1	SNP	p	D95N	0	.	.	283	285	GAC	487	489	GAC	64;64;64	G;A;C	37;36;36	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_K_01388	mtrR.WHO_K_01388	1	1	27	156	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1507	21.5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	132	mtrR_promoter	250	250	100.0	mtrR_promoter.l6.c17.ctg.1	900	25.1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	484	parC	2304	2304	99.7	parC.l15.c4.ctg.1	2620	34.8	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1469	1471	GCA	28;29;29	G;C;A	19;19;18	.	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	484	parC	2304	2304	99.7	parC.l15.c4.ctg.1	2620	34.8	1	SNP	p	D86N	0	.	.	256	258	GAC	422	424	GAC	49;49;49	G;A;C	33;33;34	parC.WHO_G_00206c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	484	parC	2304	2304	99.7	parC.l15.c4.ctg.1	2620	34.8	1	SNP	p	S87W	0	.	.	259	261	AGT	425	427	AGT	47;48;49	A;G;T	30;31;32	parC.WHO_G_00206c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	484	parC	2304	2304	99.7	parC.l15.c4.ctg.1	2620	34.8	1	SNP	p	S87I	0	.	.	259	261	AGT	425	427	AGT	47;48;49	A;G;T	30;31;32	parC.WHO_G_00206c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	484	parC	2304	2304	99.7	parC.l15.c4.ctg.1	2620	34.8	1	SNP	p	S87R	0	.	.	259	261	AGT	425	427	AGT	47;48;49	A;G;T	30;31;32	parC.WHO_G_00206c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	484	parC	2304	2304	99.7	parC.l15.c4.ctg.1	2620	34.8	1	SNP	p	S88P	0	.	.	262	264	TCC	428	430	TCC	49;49;49	T;C;C	32;32;34	parC.WHO_G_00206c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	911	428	parE	1986	116	99.14	parE.l6.c30.ctg.1	627	12.0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	911	428	parE	1986	1986	99.75	parE.l6.c30.ctg.2	2071	33.8	0	.	p	.	0	K383T	NONSYN	1147	1149	AAA	1205	1207	ACA	29;28;29	A;C,A;A	22;1,21;23	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	911	428	parE	1986	1986	99.75	parE.l6.c30.ctg.2	2071	33.8	0	.	p	.	0	D603A	NONSYN	1807	1809	GAC	1865	1867	GCC	20;19;19	G;C,A;C	14;0,13;15	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	911	428	parE	1986	1986	99.75	parE.l6.c30.ctg.2	2071	33.8	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1286	1288	GGC	25;26;26	G;G;C	18;19;20	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	911	428	parE	1986	404	98.09	parE.l6.c30.ctg.3	696	0.7	0	.	p	.	0	W223G	NONSYN	667	669	TGG	519	521	CGG	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	911	428	parE	1986	404	98.09	parE.l6.c30.ctg.3	696	0.7	0	.	p	.	0	H224P	NONSYN	670	672	CAT	516	518	GCC	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	911	428	parE	1986	404	98.09	parE.l6.c30.ctg.3	696	0.7	0	.	p	.	0	D227A	NONSYN	679	681	GAC	507	509	CGG	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	911	428	parE	1986	404	98.09	parE.l6.c30.ctg.3	696	0.7	0	.	p	.	0	Y232N	NONSYN	694	696	TAT	492	494	TGC	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	911	428	parE	1986	404	98.09	parE.l6.c30.ctg.3	696	0.7	0	.	p	.	0	K505T	NONSYN	1513	1515	AAA	153	155	ACA	1;1;1	A;C;A	0;0;1	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	911	428	parE	1986	450	95.97	parE.l6.c30.ctg.4	726	1.7	0	.	p	.	0	D511V	NONSYN	1531	1533	GAT	359	361	GTT	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	911	428	parE	1986	450	95.97	parE.l6.c30.ctg.4	726	1.7	0	.	p	.	0	D513fs	FSHIFT	1537	1537	G	365	365	G	ND	ND	ND	.	.
penA.1.001	penA.1.001	1	1	27	484	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2233	40.6	1	SNP	p	A311V	0	.	.	931	933	GCA	1232	1234	GCA	57;56;56	G;C;A	36;37;38	penA.1.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.1.001	penA.1.001	1	1	27	484	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2233	40.6	1	SNP	p	I312M	0	.	.	934	936	ATC	1235	1237	ATC	57;57;57	A;T;C	39;38;40	penA.1.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.1.001	penA.1.001	1	1	27	484	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2233	40.6	1	SNP	p	V316T	0	.	.	946	948	GTG	1247	1249	GTG	58;58;58	G;T;G	37;38;40	penA.1.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.1.001	penA.1.001	1	1	27	484	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2233	40.6	1	SNP	p	V316P	0	.	.	946	948	GTG	1247	1249	GTG	58;58;58	G;T;G	37;38;40	penA.1.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.1.001	penA.1.001	1	1	27	484	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2233	40.6	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1751	1753	ACC	41;42;41	A;C;C	25;27;25	penA.1.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.1.001	penA.1.001	1	1	27	484	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2233	40.6	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1805	1807	GCG	24;24;24	G;C;G	16;13;14	penA.1.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.1.001	penA.1.001	1	1	27	484	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2233	40.6	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1805	1807	GCG	24;24;24	G;C;G	16;13;14	penA.1.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.1.001	penA.1.001	1	1	27	484	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2233	40.6	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1928	1930	GGC	20;20;20	G;G;C	15;14;13	penA.1.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.1.001	penA.1.001	1	1	27	484	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2233	40.6	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1937	1939	GGC	15;15;13	G;G;C	10;10;8	penA.1.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.1.001	penA.1.001	1	1	27	484	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2233	40.6	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1955	1957	CCG	15;15;15	C;C;G	12;10;13	penA.1.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	950	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	2782	59.6	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	222	porA	1146	1146	99.83	porA.l6.c30.ctg.1	1851	21.9	0	.	p	.	0	M83fs	FSHIFT	247	247	A	692	692	C	8	C	4	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	418	porB1b	1047	1047	98.57	porB1b.l15.c4.ctg.1	1403	57.0	0	.	p	.	0	T18M	NONSYN	52	54	ACG	239	241	ATG	47;47;47	A;T;G	36;34;33	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	418	porB1b	1047	1047	98.57	porB1b.l15.c4.ctg.1	1403	57.0	0	.	p	.	0	K143Q	NONSYN	427	429	AAA	614	616	CAA	70;70;70	C;A;A	44;43;42	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	418	porB1b	1047	1047	98.57	porB1b.l15.c4.ctg.1	1403	57.0	0	.	p	.	0	E212D	NONSYN	634	636	GAA	821	823	GAT	127;127;127	G;A;T	78;79;76	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	418	porB1b	1047	1047	98.57	porB1b.l15.c4.ctg.1	1403	57.0	0	.	p	.	0	H213G	NONSYN	637	639	CAT	824	826	GGT	125;126;126	G;G;T	77;77;76	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	418	porB1b	1047	1047	98.57	porB1b.l15.c4.ctg.1	1403	57.0	0	.	p	.	0	V215A	NONSYN	643	645	GTT	830	832	GCT	125;125;125	G;C,A;T	79;78,1;80	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	418	porB1b	1047	1047	98.57	porB1b.l15.c4.ctg.1	1403	57.0	0	.	p	.	0	S220T	NONSYN	658	660	AGC	845	847	ACT	87;87;84	A,C;C;T,C	47,1;55;49,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	418	porB1b	1047	1047	98.57	porB1b.l15.c4.ctg.1	1403	57.0	0	.	p	.	0	R257M	NONSYN	769	771	AGG	956	958	ATG	60;60;60	A;T;G	39;39;39	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	418	porB1b	1047	1047	98.57	porB1b.l15.c4.ctg.1	1403	57.0	0	.	p	.	0	R258S	NONSYN	772	774	AGG	959	961	AGC	59;58;58	A;G;C	35;36;36	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	418	porB1b	1047	1047	98.57	porB1b.l15.c4.ctg.1	1403	57.0	0	.	p	.	0	A259G	NONSYN	775	777	GCT	962	964	GGT	58;58;58	G;G;T	36;37;37	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	418	porB1b	1047	1047	98.57	porB1b.l15.c4.ctg.1	1403	57.0	0	.	p	.	0	D297N	NONSYN	889	891	GAC	1076	1078	AAC	58;58;59	A;A;C,A	37;37;37,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	418	porB1b	1047	1047	98.57	porB1b.l15.c4.ctg.1	1403	57.0	1	SNP	p	G120K	0	.	.	358	360	GGC	545	547	GGC	51;51;50	G;G,A;C	33;34,1;33	porB1b.WHO_P_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	1498	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4934	58.2	1	SNP	p	H553N	0	.	.	1657	1659	CAT	1862	1864	CAT	48;47;47	C;A,C,T;T	33;31,1,1;35	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_F_02142c	rpsJ.WHO_F_02142c	1	1	27	150	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1162	26.4	1	SNP	p	V57M	0	.	.	169	171	GTG	615	617	GTG	61;61;61	G;T;G	39;40;37	rpsJ.WHO_F_02142c:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
